Skip to main content
  • EU's Tainted-Sartan Ban; Praluent Price Cut; Metoprolol Shortage Relieved?

    Recent developments of interest in cardiovascular medicine

    European regulators decided to ban any sartan with any level of contamination with probable carcinogenic nitrosamines, but is allowing a 2-year grace period to change manufacturing processes before enforcement. (in-Pharma Technologist.com)

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details